Enhanced recovery after pancreatic surgery: A prospective randomized controlled clinical trial


Ergenç M., Karpuz S., Ergenc M., Yegen C.

JOURNAL OF SURGICAL ONCOLOGY, cilt.124, sa.7, ss.1070-1076, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 124 Sayı: 7
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1002/jso.26614
  • Dergi Adı: JOURNAL OF SURGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1070-1076
  • Anahtar Kelimeler: enhanced recovery after surgery, ERAS, pancreas cancer, pancreaticoduodenectomy, pancreatectomy, INTERNATIONAL STUDY-GROUP, PERIOPERATIVE CARE, PANCREATICODUODENECTOMY, COMPLICATIONS, IMPACT, DEFINITION
  • Marmara Üniversitesi Adresli: Evet

Özet

Background and Objectives The enhanced recovery after surgery (ERAS) protocol is a perioperative care bundle designed to achieve early healing after surgical procedures. This study aims to investigate the effect of the ERAS protocol on postoperative complications, length of hospital stay (LOS), and readmission rates in pancreatic surgery patients. Methods The study was designed as a prospective and randomized controlled study between January 2016 and November 2018 on pancreatic surgery patients. A total of 38 patients were analyzed, 18 of whom were in the ERAS group and 20 in the control group. Patient demographics, intraoperative variables, and postoperative outcomes were recorded. Results The groups were similar regarding age, sex, surgery type, American Society of Anesthesiologists scores, and laboratory results. There was no significant difference in the intraoperative variables. Early oral feeding was preferred, mostly in the ERAS group compared to the control group. Perioperative complication rates, including delayed gastric emptying and pancreatic fistula, LOS, and readmission rates, were similar between the two groups. Conclusions The ERAS protocol provided a minimal decrease in the total complication rates and had no effect on severe complications. Therefore, the ERAS protocol seems feasible and can be applied safely in pancreatic surgery patients.